No. Too costly and their new business partners have different ideas for success. FUSE says they will release a PR soon to describe the future. I contacted Macular to find out if FUSE/CURE are using them in the future. They won't comment. This implies that FUSE has multiple deals in the works and both companies are not commenting. All this insider BS is closing doors to investors. The insiders still work the system.
News 
Market Data 
Discover 
AI
